APG Asset Management N.V. Acquires 28,808 Shares of Danaher Corporation $DHR

APG Asset Management N.V. lifted its holdings in shares of Danaher Corporation (NYSE:DHR) by 4.3% during the first quarter, HoldingsChannel reports. The firm owned 704,616 shares of the conglomerate’s stock after purchasing an additional 28,808 shares during the quarter. APG Asset Management N.V.’s holdings in Danaher were worth $133,722,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. GHP Investment Advisors Inc. lifted its holdings in Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC purchased a new stake in Danaher during the fourth quarter valued at about $27,000. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in Danaher during the first quarter valued at about $31,000. Finally, Dunhill Financial LLC lifted its holdings in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after purchasing an additional 67 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 3.8%

DHR stock opened at $211.7060 on Friday. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average is $200.67 and its 200 day moving average is $199.53. The stock has a market cap of $151.59 billion, a price-to-earnings ratio of 45.04, a price-to-earnings-growth ratio of 2.85 and a beta of 0.73. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Evercore ISI dropped their price objective on shares of Danaher from $230.00 to $226.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Wells Fargo & Company decreased their price target on Danaher from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 23rd. UBS Group decreased their price target on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft decreased their price target on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Finally, Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target on the stock in a research report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.